Moderna
Leadership Changes at Agios and Moderna: Board Resignation and New Marketing Chief
David Schenkein, Agios Pharmaceuticals, board resignation, Moderna, Amy Mahery, chief marketing officer, pharmaceutical industry, leadership changes
HHS Awards Moderna $590 Million to Expedite Bird Flu Vaccine Development
Moderna, HHS, Bird Flu Vaccine, Avian Influenza, mRNA Vaccine, Pandemic Preparedness
Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline
Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.
Moderna Co-Founder Kenneth Chien’s New Biotech Secures $950M RNA Deal with Etherna
Kenneth Chien, Moderna, Etherna, RNA deal, biotech, mRNA therapies
Moderna CEO Reflects on 2024 Challenges and Advances in Shareholder Letter
Moderna, shareholder letter, 2024 review, RSV vaccine, COVID-19 vaccine, mRNA medicines, Stéphane Bancel
Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants
Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee
Moderna’s COVID-19 Vaccine Sales Exceed Expectations, but RSV Vaccine Falls Short
Moderna, COVID-19 vaccine, RSV vaccine, vaccine sales, pharmaceutical industry
Moderna Faces Second Consecutive Marketing Breach for Spikevax Vaccine
Moderna, Spikevax, Marketing Breach, COVID-19 Vaccine, Regulatory Compliance
Moderna Revamps R&D Strategy with $1.1B Cuts and Pipeline Overhaul
Moderna, R&D cuts, pipeline overhaul, biotechnology, pharmaceutical industry, cost reduction, research and development.
GSK Abandons HSV Vaccine Development After Phase 2 Failure, Paving Way for Moderna and BioNTech
GSK, HSV vaccine, phase 2 failure, Moderna, BioNTech, mRNA vaccines, herpes simplex virus